Genentech has added another piece of the trial puzzle for its MEK inhibitor cobimetinib. The big Roche subsidiary's partner Exelixis announced early Tuesday that the drug combined with Zelboraf hit the mark in a Phase III study, offering a statistically significant overall survival benefit among advanced melanoma patients carrying a BRAF V600 mutation.
Fresh on the heels of its inclusion in this year's Fierce 15, New Haven, CT-based Arvinas has pulled the wraps off a new partnership with Genentech that comes with a $300 million package of milestones.
Japan's Chugai Pharmaceutical and Switzerland's Roche's and its Genentech unit received U.S. FDA acceptance for a new drug application of alectinib for ALK positive advanced non-small cell lung cancer in patients for whom crizotinib is no longer an option.
Genentech has agreed to lend its closely-watched checkpoint inhibitor atezolizumab to Syndax for a combo study with the Waltham, MA-based biotech's lead drug entinostat for triple-negative breast cancer, just three days after Syndax landed an $80 million crossover round.
Roche is spotlighting another success for its PD-L1 checkpoint drug atezolizumab, with company execs applauding a positive finish in a big mid-stage study in non-small cell lung cancer. The news follows a string of steady pipeline advancements for a drug that has emerged as the pharma giant's biggest single late-stage blockbuster contender.
Just two days after striking a partnership with Merck, Immune Design has come back with another marquee pact. The West Coast biotech has inked a deal to partner its immune system activator CMB305 with Genentech's anti-PD-L1 star atezolizumab (MPDL3280A) in a Phase II study for soft tissue sarcoma.
Clovis Oncology is planning to test whether its oral lung cancer drug can work in tandem with a closely watched injectable treatment from Roche's Genentech division, hoping to expand the potential for its breakthrough-designated therapy.
AC Immune has picked up a milestone payment in its CHF 400 million ($421 million) anti-tau collaboration with Genentech. The Roche subsidiary handed over the cash after selecting a tau-targeting antibody developed in the collaboration to advance toward the clinic.
The FDA has opted to delay its review of cobimetinib in order to give regulators more time to consider additional Phase III data provided by Genentech.
Behind the headlines here at ASCO, you'll find one of the biggest players in immuno-oncology quietly positioning itself to grab a leading role in the fast-emerging market.